An observational study in Acromegaly, sponsored by Copenhagen University Hospital, Rigshospitalet. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-28.
Sponsored by Copenhagen University Hospital, Rigshospitalet · Observational
Hypothesis: Fractionated stereotactic radiotherapy is a safe therapy for treatment of patients with acromegaly in terms of both tumour control and biochemical remission
An audit was done on 34 patients with acromegaly (consecutive cohorte) treated with fractionated stereotactic radiotherapy in Rigshospitalet/National University Hospital, Copenhagen, Denmark. All patients had MR control regularly to monitor tunour control, and biochemical control assessed by growth hormone measurements during an oral glucose tolerance test. Furthermore all other pituitary axes were tested for sufficiency and concomitant medication likewise registered. The 7 year interim analysis demonstrated an acceptable tumour control and biochemical remission profile, and most patient had subsequent withdrawal of somatostatin analogue- and growth hormone receptor antagonis therapy. The observational study will continue with a new update in approx 2 years
203 studies on the registry are indexed under Acromegaly; 19 are open to participants now.
This study's enrollment of 34 is below the median of 100 across 81 observational studies indexed under Acromegaly.
Browse Acromegaly studies →Copenhagen University Hospital, Rigshospitalet is the lead sponsor of 34 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
34 patients with active acromegaly despite medical therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
adults active acromegaly pituitary tumour on MRI biochemical activity -
Exclusion Criteria:
pregnancy no visible tumour on MRI
-
patients with active acromegaly
Radiation: fractionated stereotactic radiotherapy
Audit of outcome
Tumour control by pituitary MRI
Time frame: 7 years
biochemical remission
Time frame: 10 years
Affection of other pituitary axes
Time frame: 10 years
withdrawal of somatostatin analogue and growth hormone receptor antagomist
Time frame: 10 years
The record gives a start of Jan 2002, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Copenhagen University Hospital, Rigshospitalet